{"transactions":[{"id":831863,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56787,"kind":"person","name":"Prabhu Narayan","position":1,"cik":"0001829831","reported_name":"Prabhu Narayan","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-20T21:00:47.000Z","date":"2026-03-18","kind":"grant","planned":false,"acquired":true,"shares":40925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was made on March 18, 2026 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":40925,"derivative":{"exercise_price":1.87,"expiration_date":"2036-03-17","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":40925},"source":{"system":"sec-edgar","filing":"0001437749-26-009260","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774926009260/rdgdoc.xml","form_type":"4"}},{"id":832421,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-20T17:00:20.000Z","date":"2026-03-18","kind":"grant","planned":false,"acquired":true,"shares":40925,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was made on the Grant Date in accordance with the terms of the Issuer's 2020 Plan. The option provides for vesting as follows: (i) 12,789 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 28,136 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":40925,"derivative":{"exercise_price":1.87,"expiration_date":"2036-03-17","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":40925},"source":{"system":"sec-edgar","filing":"0001437749-26-009258","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774926009258/rdgdoc.xml","form_type":"4"}},{"id":832420,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-20T17:00:20.000Z","date":"2026-03-18","kind":"grant","planned":false,"acquired":true,"shares":109150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This option award was made on March 18, 2026 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was made on March 18, 2026 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option provides for vesting as follows: (i) 34,110 of the shares subject to the option are immediately vested on the Grant Date, and (ii) 75,040 shares subject to the option will vest in equal installments on the last day of each month from April 2026 to December 2028. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":109150,"derivative":{"exercise_price":1.87,"expiration_date":"2036-03-17","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":109150},"source":{"system":"sec-edgar","filing":"0001437749-26-009258","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774926009258/rdgdoc.xml","form_type":"4"}},{"id":961740,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":67889,"kind":"person","name":"Funtleyder Leslie D.","position":1,"cik":"0001775394","reported_name":"Funtleyder Leslie D.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-12-19T21:18:22.000Z","date":"2025-12-18","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award (the \"Option\") was made in accordance with the terms of the 2020 Equity Incentive Plan (the \"2020 Plan\") of Reviva Pharmaceuticals Holdings, Inc. (the \"Company\"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share (\"Common Stock\"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":0.5848,"expiration_date":"2035-12-17","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-25-038446","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925038446/rdgdoc.xml","form_type":"4"}},{"id":962109,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71102,"kind":"person","name":"Margolin Richard A","position":1,"cik":"0001822761","reported_name":"Margolin Richard A","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-12-19T16:18:05.000Z","date":"2025-12-18","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award (the \"Option\") was made in accordance with the terms of the 2020 Equity Incentive Plan (the \"2020 Plan\") of Reviva Pharmaceuticals Holdings, Inc. (the \"Company\"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share (\"Common Stock\"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":0.5848,"expiration_date":"2035-12-17","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-25-038445","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822761/000143774925038445/rdgdoc.xml","form_type":"4"}},{"id":962104,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71100,"kind":"person","name":"Patel Purav","position":1,"cik":"0001818246","reported_name":"Patel Purav","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-12-19T16:17:45.000Z","date":"2025-12-18","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award (the \"Option\") was made in accordance with the terms of the 2020 Equity Incentive Plan (the \"2020 Plan\") of Reviva Pharmaceuticals Holdings, Inc. (the \"Company\"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share (\"Common Stock\"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":0.5848,"expiration_date":"2035-12-17","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-25-038444","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818246/000143774925038444/rdgdoc.xml","form_type":"4"}},{"id":962479,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-12-19T16:17:26.000Z","date":"2025-12-18","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award (the \"Option\") was made in accordance with the terms of the 2020 Equity Incentive Plan (the \"2020 Plan\") of Reviva Pharmaceuticals Holdings, Inc. (the \"Company\"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share (\"Common Stock\"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":0.5848,"expiration_date":"2035-12-17","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-25-038443","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000143774925038443/rdgdoc.xml","form_type":"4"}},{"id":1263198,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56787,"kind":"person","name":"Prabhu Narayan","position":1,"cik":"0001829831","reported_name":"Narayan Prabhu","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-18T21:30:51.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":194250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made on February 13, 2025 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option provides for vesting as follows: (i) 80,938 of the shares subject to the option are immediately vested on the Grant Date, (ii) 89,043 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 24,269 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":194250,"derivative":{"exercise_price":1.8,"expiration_date":"2035-02-12","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":194250},"source":{"system":"sec-edgar","filing":"0001437749-25-004221","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774925004221/rdgdoc.xml","form_type":"4"}},{"id":1263954,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-18T16:30:30.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":181500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This option award was made on the Grant Date in accordance with the terms of the 2020 Plan. The option provides for vesting as follows:  (i) 75,625 of the shares subject to the option are immediately vested on the Grant Date, (ii) 83,195 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 22,680 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was made on the Grant Date in accordance with the terms of the 2020 Plan. The option provides for vesting as follows:  (i) 75,625 of the shares subject to the option are immediately vested on the Grant Date, (ii) 83,195 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 22,680 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":181500,"derivative":{"exercise_price":1.8,"expiration_date":"2035-02-12","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":181500},"source":{"system":"sec-edgar","filing":"0001437749-25-004220","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774925004220/rdgdoc.xml","form_type":"4"}},{"id":1263953,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-18T16:30:30.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":519000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This option award was made on February 13, 2025 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option provides for vesting as follows:  (i) 216,125 of the shares subject to the option are immediately vested on the Grant Date, (ii) 237,882 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 64,993 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was made on February 13, 2025 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option provides for vesting as follows:  (i) 216,125 of the shares subject to the option are immediately vested on the Grant Date, (ii) 237,882 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026, and (iii) 64,993 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027. The exercise price is based on the closing price of the Issuer's common stock, par value $0.0001 per share, on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":519000,"derivative":{"exercise_price":1.8,"expiration_date":"2035-02-12","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":519000},"source":{"system":"sec-edgar","filing":"0001437749-25-004220","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774925004220/rdgdoc.xml","form_type":"4"}},{"id":1333415,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":67889,"kind":"person","name":"Funtleyder Leslie D.","position":1,"cik":"0001775394","reported_name":"Funtleyder Leslie D.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-12-12T21:35:03.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award (the \"Option\") was made in accordance with the terms of the 2020 Equity Incentive Plan (the \"2020 Plan\") of Reviva Pharmaceuticals Holdings, Inc. (the \"Company\"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock (\"Common Stock\") subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":2.52,"expiration_date":"2034-12-09","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-24-037370","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924037370/rdgdoc.xml","form_type":"4"}},{"id":1334063,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71100,"kind":"person","name":"Patel Purav","position":1,"cik":"0001818246","reported_name":"Patel Purav","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-12-12T16:35:57.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award (the \"Option\") was made in accordance with the terms of the 2020 Equity Incentive Plan (the \"2020 Plan\") of Reviva Pharmaceuticals Holdings, Inc. (the \"Company\"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock (\"Common Stock\") subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":2.52,"expiration_date":"2034-12-09","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-24-037372","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818246/000143774924037372/rdgdoc.xml","form_type":"4"}},{"id":1334441,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2024-12-12T16:35:30.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award (the \"Option\") was made in accordance with the terms of the 2020 Equity Incentive Plan (the \"2020 Plan\") of Reviva Pharmaceuticals Holdings, Inc. (the \"Company\"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock (\"Common Stock\") subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":2.52,"expiration_date":"2034-12-09","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-24-037371","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000143774924037371/rdgdoc.xml","form_type":"4"}},{"id":1334075,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71102,"kind":"person","name":"Margolin Richard A","position":1,"cik":"0001822761","reported_name":"Margolin Richard A","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2024-12-12T16:34:45.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award (the \"Option\") was made in accordance with the terms of the 2020 Equity Incentive Plan (the \"2020 Plan\") of Reviva Pharmaceuticals Holdings, Inc. (the \"Company\"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock (\"Common Stock\") subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":2.52,"expiration_date":"2034-12-09","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-24-037369","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822761/000143774924037369/rdgdoc.xml","form_type":"4"}},{"id":1404508,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56787,"kind":"person","name":"Prabhu Narayan","position":1,"cik":"0001829831","reported_name":"Narayan Prabhu","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-17T21:01:27.000Z","date":"2024-09-15","kind":"grant","planned":false,"acquired":true,"shares":96519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an option award (the \"Option\") granted to Mr. Narayan Prabhu, the Issuer's Chief Financial Officer (the \"Reporting Person\"), by the Issuer's compensation committee (the \"Compensation Committee\") on September 15, 2024 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Mr. Prabhu for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The Option, which is fully vested on the Grant Date, represents payment of Mr. Prabhu's incentive bonus earned for 2023. The exercise price of the Option is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option award (the \"Option\") granted to Mr. Narayan Prabhu, the Issuer's Chief Financial Officer (the \"Reporting Person\"), by the Issuer's compensation committee (the \"Compensation Committee\") on September 15, 2024 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Mr. Prabhu for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The Option, which is fully vested on the Grant Date, represents payment of Mr. Prabhu's incentive bonus earned for 2023. The exercise price of the Option is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan."}],"balance_after":96519,"derivative":{"exercise_price":1.2,"expiration_date":"2034-09-14","underlying":"Common Stock, par value $0.0001 per shae","underlying_shares":96519},"source":{"system":"sec-edgar","filing":"0001437749-24-029387","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924029387/rdgdoc.xml","form_type":"4"}},{"id":1405287,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-17T17:01:57.000Z","date":"2024-09-15","kind":"grant","planned":false,"acquired":true,"shares":77843,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Compensation Committee on September 15, 2024, in accordance with the terms of the 2020 Plan. On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Ms. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Compensation Committee on September 15, 2024, in accordance with the terms of the 2020 Plan. On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Ms. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan."}],"balance_after":77843,"derivative":{"exercise_price":1.2,"expiration_date":"2034-09-14","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":77843},"source":{"system":"sec-edgar","filing":"0001437749-24-029388","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774924029388/rdgdoc.xml","form_type":"4"}},{"id":1405286,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-17T17:01:57.000Z","date":"2024-09-15","kind":"grant","planned":false,"acquired":true,"shares":158451,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the \"Reporting Person\"), by the Issuer's compensation committee (the \"Compensation Committee\") on September 15, 2024 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Dr. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the \"Reporting Person\"), by the Issuer's compensation committee (the \"Compensation Committee\") on September 15, 2024 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). On the Grant Date, the Compensation Committee determined the amount of incentive bonus earned by Dr. Bhat for 2023 and determined that the Issuer would pay the incentive bonus in the form of fully vested options in lieu of cash payment. The exercise price of the option award is based on the closing price of the Issuer's common stock on September 13, 2024, in accordance with the terms of the 2020 Plan."}],"balance_after":158451,"derivative":{"exercise_price":1.2,"expiration_date":"2034-09-14","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":158451},"source":{"system":"sec-edgar","filing":"0001437749-24-029388","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774924029388/rdgdoc.xml","form_type":"4"}},{"id":1731760,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":2,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2023-11-22T18:28:27.000Z","date":"2023-11-20","kind":"other","planned":false,"acquired":true,"shares":585366,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The common stock warrants expire on November 20, 2028, and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta R2. Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Vedanta R2. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners and exercises voting and dispositive power over the securities held by Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":585366,"derivative":{"exercise_price":5,"expiration_date":"2028-11-20","underlying":"Common Stock","underlying_shares":585366},"source":{"system":"sec-edgar","filing":"0001493152-23-042540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000149315223042540/ownership.xml","form_type":"4"}},{"id":1731759,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":2,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2023-11-22T18:28:27.000Z","date":"2023-11-20","kind":"other","planned":false,"acquired":true,"shares":585366,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta R2. Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Vedanta R2. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners and exercises voting and dispositive power over the securities held by Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":585366,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":585366},"source":{"system":"sec-edgar","filing":"0001493152-23-042540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000149315223042540/ownership.xml","form_type":"4"}},{"id":1741863,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":67889,"kind":"person","name":"Funtleyder Leslie D.","position":1,"cik":"0001775394","reported_name":"Funtleyder Leslie D.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-11-14T21:21:02.000Z","date":"2023-11-13","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":6.04,"expiration_date":"2033-11-12","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-23-031992","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923031992/rdgdoc.xml","form_type":"4"}},{"id":1742417,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71102,"kind":"person","name":"Margolin Richard A","position":1,"cik":"0001822761","reported_name":"Margolin Richard A","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-11-14T16:20:15.000Z","date":"2023-11-13","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":6.04,"expiration_date":"2033-11-12","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-23-031989","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822761/000143774923031989/rdgdoc.xml","form_type":"4"}},{"id":1742416,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71100,"kind":"person","name":"Patel Purav","position":1,"cik":"0001818246","reported_name":"Patel Purav","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-11-14T16:19:24.000Z","date":"2023-11-13","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":6.04,"expiration_date":"2033-11-12","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-23-031986","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818246/000143774923031986/rdgdoc.xml","form_type":"4"}},{"id":1742835,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-11-14T16:18:50.000Z","date":"2023-11-13","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":6.04,"expiration_date":"2033-11-12","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-23-031985","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000143774923031985/rdgdoc.xml","form_type":"4"}},{"id":1912026,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56787,"kind":"person","name":"Prabhu Narayan","position":1,"cik":"0001829831","reported_name":"Narayan Prabhu","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-27T20:30:21.000Z","date":"2023-04-25","kind":"grant","planned":false,"acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option award granted to Mr. Narayan Prabhu, the Issuer's Chief Financial Officer (the \"Reporting Person\"), by the Issuer's compensation committee on April 25, 2023 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":170000,"derivative":{"exercise_price":6.74,"expiration_date":"2033-04-24","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001437749-23-011378","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774923011378/rdgdoc.xml","form_type":"4"}},{"id":1912428,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-27T16:31:00.000Z","date":"2023-04-25","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an option award granted to Ms. Seema Bhat, the Issuer's Vice President for Program & Portfolio Management and the spouse of the Reporting Person, by the Issuer's compensation committee on April 25, 2023 (the \"Grant Date\") in accordance with the terms of the 2020 Plan. The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":150000,"derivative":{"exercise_price":6.74,"expiration_date":"2033-04-24","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001437749-23-011381","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774923011381/rdgdoc.xml","form_type":"4"}},{"id":1912427,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56844,"kind":"person","name":"Bhat Laxminarayan","position":1,"cik":"0001818245","reported_name":"Bhat Laxminarayan","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-04-27T16:31:00.000Z","date":"2023-04-25","kind":"grant","planned":false,"acquired":true,"shares":443000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an option award granted to Dr. Laxminarayan Bhat, the Issuer's President and Chief Executive Officer (the \"Reporting Person\"), by the Issuer's compensation committee on April 25, 2023 (the \"Grant Date\") in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The option vested as to fifty percent (50%) of the shares subject thereto on the Grant Date, and will vest as to an additional 1.389% of the shares subject thereto on the last day of each month thereafter. The exercise price is based on the closing price of the Issuer's common stock on the Grant Date in accordance with the terms of the 2020 Plan."}],"balance_after":443000,"derivative":{"exercise_price":6.74,"expiration_date":"2033-04-24","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":443000},"source":{"system":"sec-edgar","filing":"0001437749-23-011381","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818245/000143774923011381/rdgdoc.xml","form_type":"4"}},{"id":2108764,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71100,"kind":"person","name":"Patel Purav","position":1,"cik":"0001818246","reported_name":"Patel Purav","relationship":{"director":true}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-11-21T16:15:22.000Z","date":"2022-11-18","kind":"purchase","acquired":true,"shares":3000,"price":4.69,"value":14070.0,"ownership":{"direct":true},"balance_after":43547,"source":{"system":"sec-edgar","filing":"0001437749-22-027849","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818246/000143774922027849/rdgdoc.xml","form_type":"4"}},{"id":2117357,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":67889,"kind":"person","name":"Funtleyder Leslie D.","position":1,"cik":"0001775394","reported_name":"Funtleyder Leslie D.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-11-14T14:00:22.000Z","date":"2022-11-10","kind":"grant","acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":3900,"derivative":{"exercise_price":5.13,"expiration_date":"2032-11-09","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001437749-22-027080","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922027080/rdgdoc.xml","form_type":"4"}},{"id":2118769,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2022-11-14T10:34:37.000Z","date":"2022-11-10","kind":"grant","acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":3900,"derivative":{"exercise_price":5.13,"expiration_date":"2032-11-09","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001437749-22-027114","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000143774922027114/rdgdoc.xml","form_type":"4"}},{"id":2118152,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71100,"kind":"person","name":"Patel Purav","position":1,"cik":"0001818246","reported_name":"Patel Purav","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-11-14T09:01:10.000Z","date":"2022-11-10","kind":"grant","acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":3900,"derivative":{"exercise_price":5.13,"expiration_date":"2032-11-09","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001437749-22-027082","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818246/000143774922027082/rdgdoc.xml","form_type":"4"}},{"id":2118173,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71102,"kind":"person","name":"Margolin Richard A","position":1,"cik":"0001822761","reported_name":"Margolin Richard A","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-11-14T09:00:48.000Z","date":"2022-11-10","kind":"grant","acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":3900,"derivative":{"exercise_price":5.13,"expiration_date":"2032-11-09","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001437749-22-027081","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822761/000143774922027081/rdgdoc.xml","form_type":"4"}},{"id":2146924,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56787,"kind":"person","name":"Prabhu Narayan","position":1,"cik":"0001829831","reported_name":"Narayan Prabhu","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-10-03T21:01:57.000Z","date":"2022-09-30","kind":"purchase","acquired":true,"shares":50000,"price":1.66,"value":83000.0,"ownership":{"direct":true},"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001437749-22-023485","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922023485/rdgdoc.xml","form_type":"4"}},{"id":2161581,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":513834,"price":0.0001,"value":51.3834,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The common stock warrants expire on September 8, 2027 and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":513834,"derivative":{"exercise_price":2.4,"expiration_date":"2027-09-08","underlying":"Common Stock","underlying_shares":513834},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2161580,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":869565,"price":0.0001,"value":86.9565,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The common stock warrants expire on September 8, 2027 and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":869565,"derivative":{"exercise_price":2.4,"expiration_date":"2027-09-08","underlying":"Common Stock","underlying_shares":869565},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2161579,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":513834,"price":2.5299,"value":1299948.6366,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":513834,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":513834},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2161578,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":869565,"price":2.5299,"value":2199912.4935,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":869565,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":869565},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2218470,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56787,"kind":"person","name":"Prabhu Narayan","position":1,"cik":"0001829831","reported_name":"Narayan Prabhu","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-06-30T21:52:37.000Z","date":"2022-06-30","kind":"purchase","acquired":true,"shares":50000,"price":1.2134,"value":60670.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.37 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001437749-22-016306","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774922016306/rdgdoc.xml","form_type":"4"}},{"id":2476687,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":67889,"kind":"person","name":"Funtleyder Leslie D.","position":1,"cik":"0001775394","reported_name":"Funtleyder Leslie D.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-12-10T21:30:51.000Z","date":"2021-12-08","kind":"grant","acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":5300,"derivative":{"exercise_price":3.78,"expiration_date":"2031-12-07","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001437749-21-028318","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774921028318/rdgdoc.xml","form_type":"4"}},{"id":2477718,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-10T16:49:00.000Z","date":"2021-12-08","kind":"grant","acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":5300,"derivative":{"exercise_price":3.78,"expiration_date":"2031-12-07","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001062993-21-012667","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321012667/form4.xml","form_type":"4"}},{"id":2477433,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71100,"kind":"person","name":"Patel Purav","position":1,"cik":"0001818246","reported_name":"Patel Purav","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-12-10T16:32:02.000Z","date":"2021-12-08","kind":"grant","acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":5300,"derivative":{"exercise_price":3.78,"expiration_date":"2031-12-07","underlying":"Common Stock, par value $0.001 per share","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001437749-21-028321","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818246/000143774921028321/rdgdoc.xml","form_type":"4"}},{"id":2477452,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71102,"kind":"person","name":"Margolin Richard A","position":1,"cik":"0001822761","reported_name":"Margolin Richard A","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-12-10T16:31:16.000Z","date":"2021-12-08","kind":"grant","acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":5300,"derivative":{"exercise_price":3.78,"expiration_date":"2031-12-07","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001437749-21-028320","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822761/000143774921028320/rdgdoc.xml","form_type":"4"}},{"id":2665448,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":67889,"kind":"person","name":"Funtleyder Leslie D.","position":1,"cik":"0001775394","reported_name":"Funtleyder Leslie D.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-06-16T20:30:43.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of thirty-three percent (33%) of the shares subject thereto upon the one year anniversary of December 14, 2020, and as to an additional thirty-three percent (33%) of the shares subject to the Option on each successive one year anniversary thereafter, provided that Awardee remains a director of the Company through each such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":4000,"derivative":{"exercise_price":4.73,"expiration_date":"2031-06-14","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001437749-21-014948","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774921014948/rdgdoc.xml","form_type":"4"}},{"id":2666962,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-16T18:04:37.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of thirty-three percent (33%) of the shares subject thereto upon the one year anniversary of December 14, 2020, and as to an additional thirty-three percent (33%) of the shares subject to the Option on each successive one year anniversary thereafter, provided that Awardee remains a director of the Company through each such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":4000,"derivative":{"exercise_price":4.73,"expiration_date":"2031-06-14","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001062993-21-005717","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005717/form4.xml","form_type":"4"}},{"id":2666569,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71100,"kind":"person","name":"Patel Purav","position":1,"cik":"0001818246","reported_name":"Patel Purav","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-06-16T16:31:29.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of thirty-three percent (33%) of the shares subject thereto upon the one year anniversary of December 14, 2020, and as to an additional thirty-three percent (33%) of the shares subject to the Option on each successive one year anniversary thereafter, provided that Awardee remains a director of the Company through each such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":4000,"derivative":{"exercise_price":4.73,"expiration_date":"2031-06-14","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001437749-21-014950","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818246/000143774921014950/rdgdoc.xml","form_type":"4"}},{"id":2666601,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71102,"kind":"person","name":"Margolin Richard A","position":1,"cik":"0001822761","reported_name":"Margolin Richard A","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-06-16T16:30:56.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of thirty-three percent (33%) of the shares subject thereto upon the one year anniversary of December 14, 2020, and as to an additional thirty-three percent (33%) of the shares subject to the Option on each successive one year anniversary thereafter, provided that Awardee remains a director of the Company through each such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":4000,"derivative":{"exercise_price":4.73,"expiration_date":"2031-06-14","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001437749-21-014949","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822761/000143774921014949/rdgdoc.xml","form_type":"4"}},{"id":2684388,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":399000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":399000,"derivative":{"exercise_price":4.125,"exercise_date":"2021-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":299250},"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}},{"id":2684387,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":931000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":931000,"derivative":{"exercise_price":4.125,"exercise_date":"2021-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":698250},"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}},{"id":2684386,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":399000,"price":3.75,"value":1496250.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":399000,"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}},{"id":2684385,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":931000,"price":3.75,"value":3491250.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":931000,"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}},{"id":2748193,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":56787,"kind":"person","name":"Prabhu Narayan","position":1,"cik":"0001829831","reported_name":"Narayan Prabhu","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-15T21:09:39.000Z","date":"2021-04-14","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of twenty-five percent (25%) of the shares subject thereto upon the one year anniversary of Mr. Prabhu's employment with the Company, and as to an additional 2.0833% of the shares on the last day of each month thereafter. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":50000,"derivative":{"exercise_price":4.3,"expiration_date":"2031-04-13","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-21-009050","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774921009050/rdgdoc.xml","form_type":"4"}},{"id":2748701,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71100,"kind":"person","name":"Patel Purav","position":1,"cik":"0001818246","reported_name":"Patel Purav","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-04-15T17:09:24.000Z","date":"2021-04-14","kind":"grant","acquired":true,"shares":15227,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of twenty-five percent (25%) of the shares subject thereto upon the one year anniversary of the date of grant, and as to an additional 2.0833% of the shares on the last day of each month thereafter. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":15227,"derivative":{"exercise_price":4.3,"expiration_date":"2031-04-13","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":15227},"source":{"system":"sec-edgar","filing":"0001437749-21-009049","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818246/000143774921009049/rdgdoc.xml","form_type":"4"}},{"id":2931929,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144382,"kind":"person","name":"Tenzing LLC","position":1,"cik":"0001744957","reported_name":"Tenzing LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":2,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144383,"kind":"person","name":"Nayar Rahul","position":3,"cik":"0001744923","reported_name":"Nayar Rahul","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2020-12-28T20:02:07.000Z","date":"2020-12-15","kind":"other","acquired":false,"shares":540500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chairman, and the managing members of the Sponsor, who have joint voting and dispositive power over the securities held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":11.5,"exercise_date":"2020-12-14","expiration_date":"2025-12-14","underlying":"Common Stock","underlying_shares":540500},"source":{"system":"sec-edgar","filing":"0001104659-20-139934","document":"tm2039398d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465920139934/tm2039398d1_4.xml","form_type":"4"}},{"id":2931928,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144382,"kind":"person","name":"Tenzing LLC","position":1,"cik":"0001744957","reported_name":"Tenzing LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":2,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144383,"kind":"person","name":"Nayar Rahul","position":3,"cik":"0001744923","reported_name":"Nayar Rahul","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2020-12-28T20:00:55.000Z","date":"2020-12-14","kind":"grant","acquired":true,"shares":197500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), the issuer changed its corporate structure and domicile by way of continuation from an exempted company incorporated under the laws of the British Virgin Islands to a corporation incorporated under the laws of the State of Delaware (the \"Domestication\"). Pursuant to the Domestication, each outstanding ordinary share of the issuer was converted into one share of the issuer's common stock (the \"common stock\") and each outstanding public warrant of the issuer was converted into a warrant to acquire the common stock. The reporting person held 1,924,250 ordinary shares prior to the Business Combination, which were converted into 1,924,500 shares of common stock upon the Domestication."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chairman, and the managing members of the Sponsor, who have joint voting and dispositive power over the securities held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":540500,"derivative":{"exercise_price":11.5,"exercise_date":"2020-12-14","expiration_date":"2025-12-14","underlying":"Common Stock","underlying_shares":197500},"source":{"system":"sec-edgar","filing":"0001104659-20-139933","document":"tm2039398d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465920139933/tm2039398d2_4.xml","form_type":"4"}},{"id":2931927,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144382,"kind":"person","name":"Tenzing LLC","position":1,"cik":"0001744957","reported_name":"Tenzing LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":2,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144383,"kind":"person","name":"Nayar Rahul","position":3,"cik":"0001744923","reported_name":"Nayar Rahul","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2020-12-28T20:00:55.000Z","date":"2020-12-14","kind":"other","acquired":true,"shares":343000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), the issuer changed its corporate structure and domicile by way of continuation from an exempted company incorporated under the laws of the British Virgin Islands to a corporation incorporated under the laws of the State of Delaware (the \"Domestication\"). Pursuant to the Domestication, each outstanding ordinary share of the issuer was converted into one share of the issuer's common stock (the \"common stock\") and each outstanding public warrant of the issuer was converted into a warrant to acquire the common stock. The reporting person held 1,924,250 ordinary shares prior to the Business Combination, which were converted into 1,924,500 shares of common stock upon the Domestication."},{"field":"kind","element":"transactionCoding","label":"F5","text":"These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer. These warrants were acquired in connection with the issuer's initial public offering. Each whole warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer. These warrants were acquired in connection with the issuer's initial public offering. Each whole warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer. These warrants were acquired in connection with the issuer's initial public offering. Each whole warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chairman, and the managing members of the Sponsor, who have joint voting and dispositive power over the securities held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":343000,"derivative":{"exercise_price":11.5,"exercise_date":"2020-12-14","expiration_date":"2025-12-14","underlying":"Common Stock","underlying_shares":343000},"source":{"system":"sec-edgar","filing":"0001104659-20-139933","document":"tm2039398d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465920139933/tm2039398d2_4.xml","form_type":"4"}},{"id":2931926,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144382,"kind":"person","name":"Tenzing LLC","position":1,"cik":"0001744957","reported_name":"Tenzing LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":2,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144383,"kind":"person","name":"Nayar Rahul","position":3,"cik":"0001744923","reported_name":"Nayar Rahul","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-28T20:00:55.000Z","date":"2020-12-14","kind":"grant","acquired":true,"shares":197500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Immediately prior to the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), the issuer changed its corporate structure and domicile by way of continuation from an exempted company incorporated under the laws of the British Virgin Islands to a corporation incorporated under the laws of the State of Delaware (the \"Domestication\"). Pursuant to the Domestication, each outstanding ordinary share of the issuer was converted into one share of the issuer's common stock (the \"common stock\") and each outstanding public warrant of the issuer was converted into a warrant to acquire the common stock. The reporting person held 1,924,250 ordinary shares prior to the Business Combination, which were converted into 1,924,500 shares of common stock upon the Domestication."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chairman, and the managing members of the Sponsor, who have joint voting and dispositive power over the securities held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":2121750,"source":{"system":"sec-edgar","filing":"0001104659-20-139933","document":"tm2039398d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465920139933/tm2039398d2_4.xml","form_type":"4"}},{"id":2951007,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-12-11T00:36:41.000Z","date":"2020-12-08","kind":"sale","acquired":false,"shares":367000,"price":10.88,"value":3992960.0,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001076809-20-000322","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000322/primary_doc.xml","form_type":"4"}},{"id":2952825,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-12-10T02:19:38.000Z","date":"2020-12-03","kind":"other","acquired":false,"shares":606360,"price":10.88,"value":6597196.8,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Redemption"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001076809-20-000307","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000307/primary_doc.xml","form_type":"4"}},{"id":2951613,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":106903,"kind":"organization","name":"Hudson Bay Capital Management LP","position":1,"cik":"0001393825","reported_name":"Hudson Bay Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109726,"kind":"person","name":"Gerber Sander","position":2,"cik":"0001416593","reported_name":"Gerber Sander","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-12-09T18:26:44.000Z","date":"2020-12-08","kind":"other","acquired":false,"shares":710000,"price":10.88,"value":7724800.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Persons elected to redeem 710,000 Ordinary Shares for cash."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by  Hudson Bay Master Fund, Ltd. (the \"Fund\").  Hudson Bay Capital Management LP (the \"Investment Manager\") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of  Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001393825-20-000141","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1416593/000139382520000141/primary_doc.xml","form_type":"4"}},{"id":2951612,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":106903,"kind":"organization","name":"Hudson Bay Capital Management LP","position":1,"cik":"0001393825","reported_name":"Hudson Bay Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109726,"kind":"person","name":"Gerber Sander","position":2,"cik":"0001416593","reported_name":"Gerber Sander","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-12-09T18:26:44.000Z","date":"2020-12-07","kind":"sale","acquired":false,"shares":50000,"price":11.51,"value":575500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $11.01 to $12.2501, inclusive.  The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by  Hudson Bay Master Fund, Ltd. (the \"Fund\").  Hudson Bay Capital Management LP (the \"Investment Manager\") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of  Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein."}],"balance_after":710000,"source":{"system":"sec-edgar","filing":"0001393825-20-000141","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1416593/000139382520000141/primary_doc.xml","form_type":"4"}},{"id":2957413,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-12-04T23:17:55.000Z","date":"2020-12-02","kind":"sale","acquired":false,"shares":261,"price":11,"value":2871.0,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":606360,"source":{"system":"sec-edgar","filing":"0001076809-20-000291","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000291/primary_doc.xml","form_type":"4"}},{"id":2963302,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-12-02T00:07:47.000Z","date":"2020-12-01","kind":"sale","acquired":false,"shares":5362,"price":11,"value":58982.0,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":606621,"source":{"system":"sec-edgar","filing":"0001076809-20-000282","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000282/primary_doc.xml","form_type":"4"}},{"id":2963301,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-12-02T00:07:47.000Z","date":"2020-11-27","kind":"sale","acquired":false,"shares":5969,"price":10.9,"value":65062.1,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":611983,"source":{"system":"sec-edgar","filing":"0001076809-20-000282","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000282/primary_doc.xml","form_type":"4"}},{"id":2966575,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-11-25T21:57:03.000Z","date":"2020-11-24","kind":"sale","acquired":false,"shares":7103,"price":10.9,"value":77422.7,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":617952,"source":{"system":"sec-edgar","filing":"0001076809-20-000259","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000259/primary_doc.xml","form_type":"4"}},{"id":2966574,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-11-25T21:57:03.000Z","date":"2020-11-23","kind":"sale","acquired":false,"shares":23611,"price":10.9,"value":257359.9,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":625055,"source":{"system":"sec-edgar","filing":"0001076809-20-000259","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000259/primary_doc.xml","form_type":"4"}},{"id":2975905,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-11-18T22:50:53.000Z","date":"2020-11-18","kind":"sale","acquired":false,"shares":896,"price":10.9,"value":9766.4,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":648666,"source":{"system":"sec-edgar","filing":"0001076809-20-000250","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000250/primary_doc.xml","form_type":"4"}},{"id":2975904,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-11-18T22:50:53.000Z","date":"2020-11-17","kind":"sale","acquired":false,"shares":127,"price":10.9,"value":1384.3,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":649562,"source":{"system":"sec-edgar","filing":"0001076809-20-000250","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000250/primary_doc.xml","form_type":"4"}},{"id":2975903,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-11-18T22:50:53.000Z","date":"2020-11-16","kind":"sale","acquired":false,"shares":305,"price":10.9,"value":3324.5,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":649689,"source":{"system":"sec-edgar","filing":"0001076809-20-000250","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000250/primary_doc.xml","form_type":"4"}},{"id":2981762,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-11-13T21:57:49.000Z","date":"2020-11-11","kind":"sale","acquired":false,"shares":5,"price":10.9,"value":54.5,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":649994,"source":{"system":"sec-edgar","filing":"0001076809-20-000244","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000244/primary_doc.xml","form_type":"4"}},{"id":2986923,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-11-10T21:47:12.000Z","date":"2020-11-06","kind":"sale","acquired":false,"shares":1,"price":10.9,"value":10.9,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":649999,"source":{"system":"sec-edgar","filing":"0001076809-20-000234","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000234/primary_doc.xml","form_type":"4"}},{"id":2993235,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-11-04T22:28:46.000Z","date":"2020-11-03","kind":"sale","acquired":false,"shares":57616,"price":10.85,"value":625133.6,"ownership":{"direct":false,"nature":"Footnote 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":650000,"source":{"system":"sec-edgar","filing":"0001076809-20-000213","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000213/primary_doc.xml","form_type":"4"}},{"id":2993234,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-11-04T22:28:46.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":1,"price":11.5,"value":11.5,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":707616,"source":{"system":"sec-edgar","filing":"0001076809-20-000213","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000213/primary_doc.xml","form_type":"4"}},{"id":2994607,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":106903,"kind":"organization","name":"Hudson Bay Capital Management LP","position":1,"cik":"0001393825","reported_name":"Hudson Bay Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109726,"kind":"person","name":"Gerber Sander","position":2,"cik":"0001416593","reported_name":"Gerber Sander","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-11-03T18:41:02.000Z","date":"2020-11-02","kind":"sale","acquired":false,"shares":50000,"price":10.87,"value":543500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by  Hudson Bay Master Fund, Ltd. (the \"Fund\").  Hudson Bay Capital Management LP (the \"Investment Manager\") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of  Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein."}],"balance_after":760000,"source":{"system":"sec-edgar","filing":"0001393825-20-000131","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1416593/000139382520000131/primary_doc.xml","form_type":"4"}},{"id":2994606,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":106903,"kind":"organization","name":"Hudson Bay Capital Management LP","position":1,"cik":"0001393825","reported_name":"Hudson Bay Capital Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109726,"kind":"person","name":"Gerber Sander","position":2,"cik":"0001416593","reported_name":"Gerber Sander","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-11-03T18:41:02.000Z","date":"2020-03-20","kind":"purchase","acquired":true,"shares":10000,"price":10.37,"value":103700.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities are held by  Hudson Bay Master Fund, Ltd. (the \"Fund\").  Hudson Bay Capital Management LP (the \"Investment Manager\") serves as the investment manager of the Fund. As such, the Investment Manager may be deemed to have beneficial ownership of the securities held by the Fund. As the managing member of the general partner of  Hudson Bay Capital Management LP, Mr. Sander Gerber may be deemed to have beneficial ownership of the securities held by the Fund. Each Reporting Person disclaims beneficial ownership of the securities held by the Fund, except to the extent of its or his pecuniary interest therein."}],"balance_after":810000,"source":{"system":"sec-edgar","filing":"0001393825-20-000131","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1416593/000139382520000131/primary_doc.xml","form_type":"4"}},{"id":3018865,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-10-01T20:53:27.000Z","date":"2020-09-29","kind":"sale","acquired":false,"shares":2,"price":11.5,"value":23.0,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":707617,"source":{"system":"sec-edgar","filing":"0001076809-20-000171","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000171/primary_doc.xml","form_type":"4"}},{"id":3026288,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-09-21T20:12:38.000Z","date":"2020-09-17","kind":"sale","acquired":false,"shares":1000,"price":10.8,"value":10800.0,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":707619,"source":{"system":"sec-edgar","filing":"0001076809-20-000162","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000162/primary_doc.xml","form_type":"4"}},{"id":3030548,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, no par value","published_at":"2020-09-16T20:59:45.000Z","date":"2020-09-14","kind":"sale","acquired":false,"shares":1,"price":10.8,"value":10.8,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":708619,"source":{"system":"sec-edgar","filing":"0001076809-20-000158","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000158/primary_doc.xml","form_type":"4"}},{"id":3148066,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":22584,"kind":"organization","name":"MIZUHO SECURITIES USA LLC","position":1,"cik":"0000812291","reported_name":"MIZUHO SECURITIES USA LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-15T15:51:33.000Z","date":"2020-05-08","kind":"sale","acquired":false,"shares":51000,"price":10.62,"value":541620.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"CIK\tName\n1785149\tMizuho Americas LLC\n1512734\tMizuho Bank, Ltd.\n1335730\tMIZUHO FINANCIAL GROUP INC"}],"balance_after":766750,"source":{"system":"sec-edgar","filing":"0000812291-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/812291/000081229120000006/primary_doc.xml","form_type":"4"}},{"id":3826902,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144382,"kind":"person","name":"Tenzing LLC","position":1,"cik":"0001744957","reported_name":"Tenzing LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-09-04T21:02:03.000Z","date":"2018-08-30","kind":"purchase","acquired":true,"shares":33000,"price":10,"value":330000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are underlying units (each unit consisting of one ordinary share and one warrant, each warrant exercisable to purchase one share) held by Tenzing LLC (the \"Sponsor\"), acquired pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer in connection with the exercise of the underwriters' over-allotment option pursuant to the issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chief Executive Officer and Chairman, respectively, and the managing members of the Sponsor, who have joint voting and dispositive power over the shares held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":1924250,"source":{"system":"sec-edgar","filing":"0001144204-18-047846","document":"tv502261_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000114420418047846/tv502261_4.xml","form_type":"4"}},{"id":3826901,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144383,"kind":"person","name":"Nayar Rahul","position":1,"cik":"0001744923","reported_name":"Nayar Rahul","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2018-09-04T21:01:21.000Z","date":"2018-08-30","kind":"purchase","acquired":true,"shares":33000,"price":10,"value":330000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are underlying units (each unit consisting of one ordinary share and one warrant, each warrant exercisable to purchase one share) held by Tenzing LLC (the \"Sponsor\"), acquired pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer in connection with the exercise of the underwriters' over-allotment option pursuant to the issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chief Executive Officer and Chairman, respectively, and the managing members of the Sponsor, who have joint voting and dispositive power over the shares held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":1924250,"source":{"system":"sec-edgar","filing":"0001144204-18-047844","document":"tv502260_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000114420418047844/tv502260_4.xml","form_type":"4"}},{"id":3827690,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Ordinary Shares","published_at":"2018-09-04T17:00:27.000Z","date":"2018-08-30","kind":"purchase","acquired":true,"shares":33000,"price":10,"value":330000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are underlying units (each unit consisting of one ordinary share and one warrant, each warrant exercisable to purchase one share) held by Tenzing LLC (the \"Sponsor\"), acquired pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer in connection with the exercise of the underwriters' over-allotment option pursuant to the issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chief Executive Officer and Chairman, respectively, and the managing members of the Sponsor, who have joint voting and dispositive power over the shares held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":1924250,"source":{"system":"sec-edgar","filing":"0001144204-18-047839","document":"tv502259_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000114420418047839/tv502259_4.xml","form_type":"4"}},{"id":3833505,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144383,"kind":"person","name":"Nayar Rahul","position":1,"cik":"0001744923","reported_name":"Nayar Rahul","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2018-08-24T21:01:37.000Z","date":"2018-08-23","kind":"purchase","acquired":true,"shares":310000,"price":10,"value":3100000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are underlying units (each unit consisting of one ordinary share and one warrant, each warrant exercisable to purchase one share) held by Tenzing LLC (the \"Sponsor\"), acquired pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chief Executive Officer and Chairman, respectively, and the managing members of the Sponsor, who have joint voting and dispositive power over the shares held by the Sponsor. These shares include up to an aggregate of 206,250 ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters' over-allotment option is not exercised in full. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":1891250,"source":{"system":"sec-edgar","filing":"0001144204-18-046300","document":"tv0501615_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000114420418046300/tv0501615_4.xml","form_type":"4"}},{"id":3833504,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144382,"kind":"person","name":"Tenzing LLC","position":1,"cik":"0001744957","reported_name":"Tenzing LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2018-08-24T21:00:50.000Z","date":"2018-08-23","kind":"purchase","acquired":true,"shares":310000,"price":10,"value":3100000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are underlying units (each unit consisting of one ordinary share and one warrant, each warrant exercisable to purchase one share) held by Tenzing LLC (the \"Sponsor\"), acquired pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chief Executive Officer and Chairman, respectively, and the managing members of the Sponsor, who have joint voting and dispositive power over the shares held by the Sponsor. These shares include up to an aggregate of 206,250 ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters' over-allotment option is not exercised in full. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":1891250,"source":{"system":"sec-edgar","filing":"0001144204-18-046296","document":"tv501623_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742927/000114420418046296/tv501623_4.xml","form_type":"4"}},{"id":3834205,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Ordinary Shares","published_at":"2018-08-24T17:01:12.000Z","date":"2018-08-23","kind":"purchase","acquired":true,"shares":310000,"price":10,"value":3100000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are underlying units (each unit consisting of one ordinary share and one warrant, each warrant exercisable to purchase one share) held by Tenzing LLC (the \"Sponsor\"), acquired pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chief Executive Officer and Chairman, respectively, and the managing members of the Sponsor, who have joint voting and dispositive power over the shares held by the Sponsor. These shares include up to an aggregate of 206,250 ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters' over-allotment option is not exercised in full. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":1891250,"source":{"system":"sec-edgar","filing":"0001144204-18-046298","document":"tv501621_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000114420418046298/tv501621_4.xml","form_type":"4"}}]}